- Home
- MCRB vs SGMO Comparison
MCRB vs SGMO Comparison
Compare MCRB & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | SGMO |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.7M | 155.1M |
| IPO Year | 2015 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MCRB | SGMO |
|---|---|---|
| Price | $15.92 | $0.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $14.33 | $5.60 |
| AVG Volume (30 Days) | 60.6K | ★ 4.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | $351,000.00 | ★ $32,875,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.53 | $0.38 |
| 52 Week High | $29.98 | $1.40 |
Technical Indicators
Market Signals| Indicator | MCRB | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 47.44 |
| Support Level | $14.90 | $0.43 |
| Resistance Level | $16.00 | $0.48 |
| Average True Range (ATR) | 0.77 | 0.02 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 82.78 | 53.88 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.